# COG NCTN Year 11 BIQSFP Progress Report

> **NIH NIH U10** · PUBLIC HEALTH INSTITUTE · 2024 · $3,527,865

## Abstract

PROJECT SUMMARY
Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the
prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood
cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number
of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous
leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma,
still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children
greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and
tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more
than 40% of the 500,000 survivors of childhood cancer (estimated as of 2020) experiencing a significant health
related quality of life complication from childhood cancer and its treatment. Thus, despite our advances,
development of new therapeutic approaches must be a priority for childhood cancer basic, translational and
clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted
exclusively to childhood and adolescent cancer research, was founded 20 years ago. The COG’s
multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220
leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National
Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work
that supports the mission of improving the outcome for all children with cancer. The COG will design and
conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the
molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using
innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic
approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies.
The COG research portfolio importantly also includes clinical trials focused on improving the quality of life for
children with cancer and childhood cancer survivors. As more than 90% of children diagnosed with cancer in
the US are treated at COG member institutions, COG has the ability to offer a diverse population of children
with cancer and their families the opportunity to participate in innovative research. This research effort includes
allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation
for discovery and accelerating the most promising research efforts conducted in laboratories around the world.
The proposal is for support of the COG Network Operations Center, c...

## Key facts

- **NIH application ID:** 11004591
- **Project number:** 3U10CA180886-11S1
- **Recipient organization:** PUBLIC HEALTH INSTITUTE
- **Principal Investigator:** Douglas S. Hawkins
- **Activity code:** U10 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $3,527,865
- **Award type:** 3
- **Project period:** 2014-04-11 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11004591

## Citation

> US National Institutes of Health, RePORTER application 11004591, COG NCTN Year 11 BIQSFP Progress Report (3U10CA180886-11S1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11004591. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*